326 results on '"Gilkes, Amanda"'
Search Results
2. Risk Stratification in Older Intensively Treated Patients With AML
Catalog
Books, media, physical & digital resources
3. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
4. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
5. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
6. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia
7. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
8. Overlapping features of therapy-related and de novo NPM1-mutated AML
9. Increased expression of RUNX3 inhibits normal human myeloid development
10. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
11. Unified classification and risk-stratification in Acute Myeloid Leukemia
12. RUNX3 overexpression inhibits normal human erythroid development
13. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
14. Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia
15. Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
16. Molecular MRD status and outcome after transplantation in NPM1-mutated AML
17. Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
18. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia
19. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
20. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
21. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
22. P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
23. S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
24. P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
25. P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
26. S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
27. Postinduction molecular MRD identifies patients with NPM1AML who benefit from allogeneic transplant in first remission
28. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
29. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
30. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
31. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia
32. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
33. FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
34. Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
35. Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
36. Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
37. A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results
38. Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux
39. FLT3inhibitors as MRD-guided salvage treatment for molecular failure in FLT3mutated AML
40. Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
41. RARα-PLZF Overcomes PLZF-Mediated Repression of CRABPI, Contributing to Retinoid Resistance in t(11;17) Acute Promyelocytic Leukemia
42. Unified classification and risk-stratification in Acute Myeloid Leukemia
43. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
44. Assessment of Minimal Residual Disease in Standard-Risk AML
45. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
46. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
47. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia
48. High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia
49. MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial
50. Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1-Mutated Myeloid Malignancies
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.